超越阳性切缘与包膜外侵犯:评估术后放化疗在可切除局部晚期头颈癌中的应用及临床影响
该回顾性观察队列研究利用美国国家癌症数据库,分析2004至2012年诊断为AJCC III至IVB期口腔、口咽、下咽及喉鳞癌、接受根治性手术及辅助放疗或放化疗、且切缘阴性无包膜外侵犯的患者(n=10,870)。47%接受辅助放化疗,放化疗较单纯放疗与总生存改善相关(HR 0.90;95%CI 0.86-0.94;P<.001),阳性淋巴结数多者获益更明显。
要点
- 切缘阴性且无包膜外侵犯的可切除局部晚期头颈癌中,47%接受辅助放化疗。
- 辅助放化疗较单纯放疗与总生存改善相关(HR 0.90;95%CI 0.86-0.94;P<.001)。
- 阳性淋巴结数多的患者从放化疗 vs 放疗中的生存获益增加。
核心结论
- 切缘阴性且无包膜外侵犯的可切除局部晚期头颈癌中辅助放化疗使用常见,实践差异大及生存差异支持开展进一步研究以指导个体化治疗。
- 阳性淋巴结数似乎是进一步研究此类患者放化疗的合适选择因素。
研究设计与样本
- 回顾性观察队列研究,使用美国国家癌症数据库。
- 纳入2004至2012年诊断的AJCC III至IVB期口腔、口咽、下咽及喉鳞癌患者,接受根治性手术及辅助放疗或放化疗。
- 分析切缘阴性且无包膜外侵犯亚组(n=10,870)。
主要发现
- 切缘阴性且无包膜外侵犯的可切除局部晚期头颈癌患者中,47%接受辅助放化疗。
- 放化疗使用根据患者年龄、对侧/ bulky颈部病变、阳性淋巴结数增加及下颈部病变等因素而显著不同。
- 放化疗较单纯放疗与总生存改善相关(HR 0.90;95%CI 0.86-0.94;P<.001)。
- 阳性淋巴结数多的患者从放化疗 vs 放疗中的生存获益增加。
关键数值与推荐
- 放化疗 vs 放疗的总生存HR 0.90(95%CI 0.86-0.94;P<.001)。
- 切缘阴性且无包膜外侵犯亚组中辅助放化疗使用率为47%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To examine recent utilization and survival outcomes associated with use of adjuvant chemoradiotherapy (CRT) for patients with resected locally advanced head and neck cancer (LAHNC) with negative surgical margins (SM negative) and no extracapsular extension (ECE). Materials and Methods We conducted a retrospective observational cohort study using the National Cancer Database evaluating patients diagnosed in 2004 to 2012 with AJCC stage III to IVB squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx treated with definitive surgery and adjuvant radiotherapy (RT) or CRT. We identified a subset of patients with SM negative and no ECE (n = 10,870). We determined factors associated with CRT use and examined overall survival of patients receiving CRT versus RT. We further evaluated survival outcomes by number of lymph nodes involved to assess whether this was associated with benefit from CRT. Results Among patients with resected LAHNC with SM negative and no ECE, 47% received adjuvant CRT. The use of CRT varied substantially according to several factors, including patient age, contralateral/bulky neck disease, increasing number of positive lymph nodes, and lower neck disease. CRT was associated with a statistically significant improvement in overall survival compared with RT alone (hazard ratio, 0.90; 95% CI, 0.86 to 0.94; P < .001). Survival benefits of CRT versus RT alone increased in patients with multiple positive lymph nodes. Conclusion The use of adjuvant CRT in patients with resected LAHNC with SM negative and no ECE is common. Substantial practice variation as well as the survival differences observed in this study support the conduct of additional research to guide personalized treatment approaches in this setting. The number of positive lymph nodes seems to be an appropriate selection factor for further investigation of CRT in such patients.
引用
- Trifiletti DM, Smith A, Mitra N, et al. Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer. J Clin Oncol. 2017. PMID: 28475848. doi:10.1200/JCO.2016.68.2336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。